Susquehanna International Group
IPSC icon

Susquehanna International Group’s Century Therapeutics IPSC Stock Holding History

Susquehanna International Group’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,300
Closed -$155K – 13019
2022
Q4 		$155K Buy
30,300
+1,000
+3% +$9.44K ﹤0.01% 10455
2022
Q3 		$290K Buy
+29,300
New +$309K ﹤0.01% 9877

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group's IPSC Position: Q1 2026 in Review

Susquehanna International Group increased its Century Therapeutics (IPSC) stake by 352% in Q1 2026, buying an estimated $371K and bringing the position to 226,687 shares worth $512K. The position accounts for ﹤0.01% of the portfolio, ranked #9599.

Susquehanna International Group first reported a position in IPSC in Q2 2021 and has held it in 10 quarters since. The position peaked at $675K in Q2 2021. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

  • Susquehanna International Group held 226,687 shares of Century Therapeutics worth $512K as of Q1 2026.
  • Susquehanna International Group bought 176,583 Century Therapeutics shares in Q1 2026, an estimated $371K.
  • Century Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9599 holding.
  • Susquehanna International Group first reported a position in Century Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • Susquehanna International Group's Century Therapeutics position peaked at $675K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.